POMALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) PREVIOUSLY TREATED WITH LENALIDOMIDE

被引：0
|
作者：
Gomez, Hernando Marta [1 ]
Gironella, Merce [2 ]
Abella, Eugenia [3 ]
Cabezudo, Elena [4 ]
Motllo, Cristina [5 ]
Garcia, Antoni [6 ]
Sarra, Josep [7 ]
Mostacedo, Silvia [8 ]
Granell, Miquel [9 ]
Rosinol, Laura [1 ]
机构：
[1] Hosp Clin Barcelona, Barcelona, Spain
[2] Hosp Valle De Hebron, Barcelona, Spain
[3] Hosp Mar, Barcelona, Spain
[4] Hosp Moises Broggi ICO Hosp, Barcelona, Spain
[5] Fundacio Althaia, Barcelona, Spain
[6] Hosp Arnau Vilanova, Lledia, Spain
[7] Hosp Joan 23, Tarragona, Spain
[8] Hosp Josep Trueta, Girona, Spain
[9] Hosp Santa Creu & Sant Pau, Barcelona, Spain
来源：
HAEMATOLOGICA | 2020年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
CO-011
引用
收藏
页码：13 / 14
页数：2
相关论文
共 50 条
  • [1] Successful retreatment with lenalidomide for relapsed and refractory multiple myeloma previously treated with bortezomib, lenalidomide and pomalidomide
    Oka, Satoko
    Ono, Kazuo
    Nohgawa, Masaharu
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2018, 43 (06) : 914 - 917
  • [2] NICE guidance on pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib
    Burke, Martyn J.
    George, Elisabeth
    Adler, Amanda I.
    [J]. LANCET ONCOLOGY, 2015, 16 (05): : 492 - 493
  • [3] POMALIDOMIDE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): EXPERIENCE CENTER
    Cuesta Garcia, A.
    [J]. HAEMATOLOGICA, 2015, 100 : 104 - 104
  • [4] Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM)
    Badros, Ashraf Z.
    Hyjek, Elizabeth
    Ma, Ning
    Lesokhin, Alexander M.
    Rapoport, Aaron P.
    Kocoglu, Mehmet H.
    Lederer, Emily
    Philip, Sunita
    Lesho, Patricia
    Johnson, Ashlee
    Dell, Cameron
    Goloubeva, Olga
    Singh, Zeba
    [J]. BLOOD, 2016, 128 (22)
  • [5] Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma
    Paludo, Jonas
    Mikhael, Joseph R.
    LaPlant, Betsy R.
    Halvorson, Alese E.
    Kumar, Shaji
    Gertz, Morie A.
    Hayman, Suzanne R.
    Buadi, Francis K.
    Dispenzieri, Angela
    Lust, John A.
    Kapoor, Prashant
    Leung, Nelson
    Russell, Stephen J.
    Dingli, David
    Go, Ronald S.
    Lin, Yi
    Gonsalves, Wilson I.
    Fonseca, Rafael
    Bergsagel, P. Leif
    Roy, Vivek
    Sher, Taimur
    Chanan-Khan, Asher A.
    Ailawadhi, Sikander
    Stewart, A. Keith
    Reeder, Craig B.
    Richardson, Paul G.
    Rajkumar, S. Vincent
    Lacy, Martha Q.
    [J]. BLOOD, 2017, 130 (10) : 1198 - 1204
  • [6] Daratumumab with Pomalidomide and Dexamethasone at First Relapse in Relapsed and/or Refractory Multiple Myeloma ( RRMM) Patients
    不详
    [J]. BLOOD, 2021, 138
  • [7] Pomalidomide Plus Dexamethasone (Pd) in the Treatment of Asian Patients with Relapsed/Refractory Myeloma (RRMM) Who Are Previously Treated with Bortezomib and Refractory to Lenalidomide - Interim Analysis of a Trial By the Asian Myeloma Network (AMN)
    Chng, Wee J.
    Kim, Kihyun
    Huang, Jeffrey
    Chim, Chor Sang
    Kosugi, Hiroshi
    Takezako, Naoki
    Sakamoto, Junichi
    Gopalakrishnan, Sathish Kumar
    Wei, Yuan
    Zhuo, Ling Ying
    Lee, Je-Jung
    Yoon, Sung-Soo
    Kim, Jin Seok
    Min, Chang-Ki
    Lee, Jae-Hoon
    Durie, Brian G. M.
    [J]. BLOOD, 2016, 128 (22)
  • [8] Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM)
    Chen, Christine I.
    Bahlis, Nizar J.
    Gasparetto, Cristina
    Tuchman, Sascha A.
    Lipe, Brea
    Baljevic, Muhamed
    Kotb, Rami
    Sutherland, Heather J.
    Bensinger, William I.
    Sebag, Michael
    LeBlanc, Richard
    Venner, Christopher P.
    Schiller, Gary J.
    Lentzsch, Suzanne
    Callander, Natalie S.
    Rossi, Adriana C.
    Sheehan, Heidi
    Van Domelen, Dane
    Kazuharu, Kai
    Wang, Hongwei
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael G.
    White, Darrell J.
    [J]. BLOOD, 2020, 136
  • [9] Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM)
    Lacy, Martha Q.
    LaPlant, Betsy R.
    Laumann, Kristina M.
    Kumar, Shaji
    Gertz, Morie A.
    Hayman, Suzanne R.
    Buadi, Francis
    Dispenzieri, Angela
    Lust, John A.
    Kapoor, Prashant
    Leung, Nelson
    Russell, Stephen J.
    Dingli, David
    Gonsalves, Wilson I.
    Fonseca, Rafael
    Bergsagel, P. Leif
    Roy, Vivek
    Sher, Taimur
    Ailawadhi, Sikander
    Chanan-Khan, Asher
    Stewart, A. Keith
    Reeder, Craig B.
    Rajkumar, S. Vincent
    Mikhael, Joseph R.
    [J]. BLOOD, 2014, 124 (21)
  • [10] Melflufen Therapy for Relapsed Refractory Multiple Myeloma (RRMM) Patients Refractory to Daratumumab and/or Pomalidomide: A Report on Early Efficacy
    Mateos, Maria-Victoria
    Blade, Joan
    Larocca, Alessandra
    Oriol, Albert
    Rodriguez, Paula
    Alegre, Adrian
    Cavo, Michele
    Moreb, Jan S.
    Paner, Agne
    Gabrail, Nashat
    Halka, Kathleen G.
    Hassoun, Hani
    Maisel, Christopher
    Mazumder, Amitabha
    Zonder, Jeffrey A.
    Ocio, Enrique M.
    Byrne, Catriona
    Harmenberg, Johan
    Thuresson, Sara
    Nordstrom, Eva
    Lindberg, Jakob
    Richardson, Paul G.
    [J]. BLOOD, 2017, 130
12345